Life Science & Biotech

Life sciences firm Hycor moving HQ, jobs to central Indiana

April 27, 2011
 IBJ Staff
California-based Hycor Biomedical Inc. plans to move its headquarters to central Indiana, creating as many as 20 jobs in the next two years, state economic development officials announced Wednesday morning.
More

Roche wins approval of HPV test

April 25, 2011
J.K. Wall
Roche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market for automated cervical cancer tests.
More

Much unknown about new Cook Group CEO

April 22, 2011
Scott Olson
Carl Cook has been tabbed to replace his father, Bill Cook, who died a week ago. But many in the Bloomington business community know little about him, which reflects the company's strict privacy policy.
More

FDA wants further testing of Lilly pancreas drug

April 16, 2011
Associated Press
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
More

Bill Cook, medical device magnate and philanthropist, dies at 80

April 15, 2011
 IBJ Staff and Associated Press
The founder of Bloomington-based life sciences giant Cook Group Inc. and the wealthiest man in Indiana leaves a legacy of dozens of historic structures saved from decay or demolition. He also was a major donor to Indiana University and its athletics department.
More

Lilly’s Bydureon wins backing of European drug panel

April 15, 2011
Bloomberg News
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
More

China making big gains in drug R&D jobs state covets

April 9, 2011
Greg Andrews
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
More

Wishard gives IT firms in health and life sciences a place to test productsRestricted Content

April 9, 2011
Chris O'Malley
TechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
More

Tax breaks approved for bioanalytical lab operator

April 7, 2011
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.'s request for a tax abatement to build a laboratory at Purdue Research Park in Indianapolis.
More

Bioanalytical researcher seeking abatement for new lab

April 5, 2011
Scott Olson
Advion, a provider of bioanalytical research and a subsidiary of Ithaca, N.Y.-based Advion BioSciences Inc., is expected to open the 22,000-square-foot lab in mid-May with 49 employees, according to the company's application.
More

Indiana college to break ground on pharmacy school

April 1, 2011
 IBJ Staff and Associated Press
Northern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
More

Scientists question claims in biotech letter

April 1, 2011
Associated Press
The widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that the public will believe his unsupported claim is true.
More

Zimmer goes on offensive against lawyers

March 30, 2011
J.K. Wall
The Warsaw-based maker of orthopedic implants has filed suit to stop a Detroit-area law firm from making allegedly false claims and using its trademarks on websites designed to attract plaintiffs to sue Zimmer over one of its knee-replacement implants called NexGen.
More

Marcadia Biotech principals ponder next course

March 22, 2011
Chris O'Malley
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
More

Drugmakers call off animal-health deal, possible asset sale

March 22, 2011
 IBJ Staff and Bloomberg News
Drugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling with regulators for a year over potential divestitures. Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies considered selling.
More

Research jobs could flow from Purdue quadRestricted Content

March 19, 2011
Marc D. Allan
Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.
More

Dow Agro thinks it has a winner

March 16, 2011
J.K. Wall
The Indianapolis-based company released more details this month about its Enlist Weed Control System, which would genetically modify corn, soybeans and cotton to be resistant to one of the most common weedkillers.
More

Lilly agrees to buy European animal health company

March 14, 2011
J.K. Wall
Elanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.
More

Product delays thwart $40M Roche purchase

March 12, 2011
J.K. Wall
Delays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring a key software vendor.
More

Purdue case highlights costs of defending intellectual propertyRestricted Content

March 12, 2011
J.K. Wall
A complicated legal case about trade secrets points up a down side to the success Indiana’s research universities have had turning their research into revenue: Large legal bills can eat much of the money.
More

Lilly suffers another bruise from Novo

March 9, 2011
J.K. Wall
The failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the highly touted diabetes drug.
More

Lilly confident of FDA approval for Amyvid, Lechleiter says

March 9, 2011
Bloomberg News
Eli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer’s disease.
More

Dow Chemical moves toward engineered corn patent

March 1, 2011
Associated Press
Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
More

UPDATE: Bioanalytical researcher opening lab in Indianapolis

March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
More

Lilly looks to double pipeline size again

February 23, 2011
J.K. Wall
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am not by any means judging whether this is a good or bad project. It's pretty simple, the developers are not showing a hardship or need for this economic incentive. It is a vacant field, the easiest for development, and the developer already has the money to invest $26 million for construction. If they can afford that, they can afford to pay property taxes just like the rest of the residents do. As well, an average of $15/hour is an absolute joke in terms of economic development. Get in high paying jobs and maybe there's a different story. But that's the problem with this ask, it is speculative and users are just not known.

  2. Shouldn't this be a museum

  3. I don't have a problem with higher taxes, since it is obvious that our city is not adequately funded. And Ballard doesn't want to admit it, but he has increased taxes indirectly by 1) selling assets and spending the money, 2) letting now private entities increase user fees which were previously capped, 3) by spending reserves, and 4) by heavy dependence on TIFs. At the end, these are all indirect tax increases since someone will eventually have to pay for them. It's mathematics. You put property tax caps ("tax cut"), but you don't cut expenditures (justifiably so), so you increase taxes indirectly.

  4. Marijuana is the safest natural drug grown. Addiction is never physical. Marijuana health benefits are far more reaching then synthesized drugs. Abbott, Lilly, and the thousands of others create poisons and label them as medication. There is no current manufactured drug on the market that does not pose immediate and long term threat to the human anatomy. Certainly the potency of marijuana has increased by hybrids and growing techniques. However, Alcohol has been proven to destroy more families, relationships, cause more deaths and injuries in addition to the damage done to the body. Many confrontations such as domestic violence and other crimes can be attributed to alcohol. The criminal activities and injustices that surround marijuana exists because it is illegal in much of the world. If legalized throughout the world you would see a dramatic decrease in such activities and a savings to many countries for legal prosecutions, incarceration etc in regards to marijuana. It indeed can create wealth for the government by collecting taxes, creating jobs, etc.... I personally do not partake. I do hope it is legalized throughout the world.

  5. Build the resevoir. If built this will provide jobs and a reason to visit Anderson. The city needs to do something to differentiate itself from other cities in the area. Kudos to people with vision that are backing this project.

ADVERTISEMENT